Neurol. praxi. 2009;10(4):254-261

Treatment of the primary insomnia from the psychiatrist point of view

doc. MUDr. Ján Praško CSc1,3,2,4, MUDr. Lucie Závěšická1, MUDr. Anežka Ticháčková3
1 Psychiatrické centrum Praha, 3. LF UK, Praha
2 Centrum neuropsychiatrických studií, Praha
3 Psychiatrická klinika FN a LF UP, Olomouc
4 3. LF UK, Praha

Primary insomnia is characterized with difficulty initiating or maintaining sleep, or non-restorative sleep, lasting at least a month in

duration. The treatment for short term insomnia with hypnotics is recommended. The use of hypnotics in treating chronic insomnia

remains controversial. The non-benzodiazepine hypnotics zolpiden, zopiclone, and zaleplon are replacing benzodiazepines as first-line

pharmacotherapy for short-term insomnia. Hypnotics should be considered only after a thorough diagnostic assessment of secondary

causes of insomnia, after sleep hygiene has been improved and after behavioral treatments has been attempted. If these approaches

are unsuccessful, then hypnotics can be used, starting with very low doses and limiting use to short periods. Some antidepressant, such

as sedating tricyclic antidepressants, mirtazapine and trazodone, are also used as sedative-hypnotic agents for the treatment of chronic

insomnia. Low nocturnal melatonin production and secretion have been documented in elderly insomniacs, and exogenous melatonin has

been shown to be beneficial in treating sleep disturbances of these patients. There are several effective treatment approaches to primary

insomnia that do not involve the use of psychopharmacs Education about normal sleep and counseling around habits for promoting

good sleep hygiene are a good but not sufficient intervention when used alone. Various relaxation therapies such as progressive muscle

relaxation can be helpful. Stimulus control behavior modification focuses on eliminating environmental cues associated with arousal.

Sleep restriction therapy is similarly aimed at reducing the amount of wake time spent in bed. Sleep deprivation helps consolidate sleep

on subsequent nights, thereby improving sleep efficiency.

Keywords: primary insomnia, education, non-benzodiazepine hypnotics, benzodiazepines, melatonin, antidepressants, sleep hygiene, relaxation, stimulus control, cognitive-behavioral therapy, sleep restriction therapy.

Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Praško J, Závěšická L, Ticháčková A. Treatment of the primary insomnia from the psychiatrist point of view. Neurol. praxi. 2009;10(4):254-261.
Download citation

References

  1. Akiskal HS. Dysthymia, cyclothymia, and related chronic subtreshold mood disorders. In: Geodet MG, López - Ibor, JJ a Andreasen NC: New Oxford Textbook of Psychiatry, Oxford University Press 2000: 736-749.
  2. Bootzin RR. Stimulus control treatment for insomnia. Proceedings of the American Psychological Association. 1972; 7: 395-396. Go to original source...
  3. Čížek J, Hosák L, Černíková L, Slabá L. Syndrom závislosti na zolpidemu. Čes Slov Psychiatrie 2000; 5: 263-266.
  4. Janicak PG. Handbook of Psychofarmacotherapy. Lippicott Williams & Wilkins. Baltimore 1999: 391 s.
  5. Kryger M, Monjan A, Bliwise D, Ancoli-Israel S. Sleep, health, and aging: bridging the gap between science and clinical practice. Geriatrics. 2004? 59: 24-26, 29-30.
  6. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007 Dec; 16(4): 372-380. Go to original source... Go to PubMed...
  7. Liappas IA, Malitas PN, Dimopoulos NP, et al. Zolpidem dependence case series: possible neurobiological mechanismus and clinical management. J Psychopharmacol 2003; 17: 131-135. Go to original source... Go to PubMed...
  8. Lichenstein KL. Sleep compression treatment of an insomnoid. Behavior Therapy 1988; 19: 625-632. Go to original source...
  9. Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chování: Diagnostická kritéria pro výzkum. (přeloženo z anglického originálu) Praha, Psychiatrické centrum 1996; Zprávy č. 134, 179 pp.
  10. Morin CM, Culbert JP, Schwartz SM. Nonfarmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am. J. Psychiatry 1994; 151: 1172-1180. Go to original source... Go to PubMed...
  11. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin. Psychol. 1995; 63: 79-89. Go to original source... Go to PubMed...
  12. National Institutes of Health State of the Science Conference statement. Manifestations and management of chronic insomnia in adults, June 13-15, 2005. Sleep. 2005; 28: 1049-1057. Go to PubMed...
  13. Praško PJ, Maršálek M, Červená K. Noci plné obav a smutku. Příručka pro lidi trpící depresí a nespavostí. Organon, 2001: 29-31.
  14. Roth T. Measuring treatment efficacy in insomnia. J Clin Psychiatry 2004; 65(suppl 8): 8-12.
  15. Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. Sleep. 2000; 23: 1-13. Go to original source...
  16. Šonka K, Tafti M, Billiard M. Polysomnografické nálezy u narkoleptiků středního a vyššího věku. Sbor. Lék., 94, 1993; č. 4, 333-344 s.
  17. Švestka J, Hypnotika. In: Hoschl C, Libiger J, Śvestka J. Psychiatrie, Praha: Tigis 2002: 732-736.
  18. Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007 Oct; 23(10): 2597-2605. Go to original source... Go to PubMed...
  19. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004; 65(suppl 8): 13-19.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.